国际专家共识:乳腺癌HER2报告聚焦HER2低表达与超低表达
该共识由国际专家制定,针对乳腺癌HER2低表达和超低表达的识别与报告提出实践推荐。基于T-DXd临床试验定义,HER2低表达为IHC 1+或IHC 2+且无基因扩增,HER2超低表达为>0%至≤10%肿瘤细胞微弱或不完整膜染色(IHC 0+伴膜染色),HER2-null为完全无染色。共识强调标准化检测、验证抗体、严格质控和病理医生培训,并建议采用结构化报告区分IHC 0、IHC 0+和HER2低表达。
要点
- HER2低表达定义为IHC 1+或IHC 2+无基因扩增,超低表达为≤10%细胞微弱膜染色。
- T-DXd已获FDA和EMA批准用于HER2低表达和超低表达转移性乳腺癌。
- CAP新模板建议区分IHC 0(无膜染色)与IHC 0+(伴膜染色)。
核心结论
- 应详细评估并报告传统HER2阴性结果,以识别可能从T-DXd获益的转移性乳腺癌患者。
- 推荐使用结构化病理报告明确区分IHC 0(null)、IHC 0+(超低表达)和HER2低表达。
研究设计与样本
- 国际专家共识,基于证据提出实践推荐,由病理专家制定。
主要发现
- T-DXd在HER2低表达(IHC 1+或IHC 2+无扩增)转移性乳腺癌中显示生存获益。
- HER2超低表达定义为>0%至≤10%肿瘤细胞微弱或不完整膜染色(IHC 0+伴膜染色)。
- HER2-null定义为完全无染色(IHC 0无膜染色)。
- FDA和EMA已将T-DXd批准扩展至HER2低表达和超低表达转移性乳腺癌。
关键数值与推荐
- HER2低表达:IHC 1+或IHC 2+且无HER2基因扩增。
- HER2超低表达:>0%至≤10%肿瘤细胞微弱或 barely perceptible 不完整膜染色(IHC 0+伴膜染色)。
- HER2-null:完全无染色(IHC 0无膜染色)。
- CAP新生物标志物报告模板推荐明确区分IHC 0无膜染色与IHC 0+伴膜染色。
临床怎么用
- 对传统HER2阴性乳腺癌应进一步细分IHC 0、IHC 0+和IHC 1+/2+无扩增,以指导T-DXd治疗选择。
- 采用验证的检测方法和标准化流程,确保低水平HER2表达的准确检出。
- 使用稳健的内外部对照和质量保证标准,并对病理医生进行专项培训。
- 采用通用结构化病理报告,清晰区分HER2 null、超低表达和低表达。
局限性
- 检测方法变异、评分可重复性和低表达质量保证标准是病理医生关注的主要问题。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The concept of "HER2-negative" breast cancer is evolving, with the recognition of HER2-low and HER2-ultralow subsets. These subsets are clinically relevant regarding treatment with the antibody-drug conjugate trastuzumab deruxtecan (T-DXd), which has shown survival benefit in patients with metastatic carcinoma with minimal HER2 protein expression that lack HER2 gene amplification by in situ hybridization. In clinical trials using T-DXd, HER2-low was defined as an immunohistochemistry (IHC) score 1+ or an IHC score 2+ without HER2 gene amplification. HER2-ultralow was defined as faint or barely perceptible, incomplete membrane staining in >0% to ≤10% of tumor cells (IHC score 0+/with membrane staining) and HER2-null as the complete absence of staining (IHC score 0/absent membrane staining). These results now necessitate more detailed evaluation and reporting of traditional "HER2-negative" results to identify patients with metastatic breast cancer who may benefit from T-DXd therapy. Both the US Food and Drug Administration and the European Medicines Agency have extended the regulatory approval of T-DXd to patients with metastatic breast cancer showing HER2-low or HER2-ultralow expressions. Updated clinical management guidelines now, therefore, incorporate the spectrum of HER2 results into treatment selection algorithms in the metastatic setting. To align histopathologic practice with these developments, the College of American Pathologists has issued a new biomarker-reporting template that recommends explicit distinction between IHC 0/absent membrane staining and IHC 0+/with membrane staining. Key concerns among pathologists include assay variability, scoring reproducibility, and quality assurance standards for accurately detecting such low levels of HER2 expression. This manuscript provides expert consensus, evidence-based practical recommendations for identifying and reporting tumors with HER2-low and HER2-ultralow expression. We emphasize standardized testing protocols, validated assays, robust internal and external controls, and focused training for pathologists. A universal structured pathology report is proposed to highlight the accurate distinction between IHC 0 (null), IHC 0+ (ultralow), and HER2-low expressions.
引用
- Rakha EA, Tan PH, Van Bockstal MR, et al. International Expert Consensus Recommendations for HER2 Reporting in Breast Cancer: Focus on HER2-Low and Ultralow Categories. Mod Pathol. 2025. PMID: 41167529. doi:10.1016/j.modpat.2025.100925
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。